Haleon sees higher sales in 2024 as FY profits come in flat

Consumer health firm Haleon on Thursday posted flat annual earnings and said it expected to grow revenue this year on higher demand.

The maker of Panadol pain relief, spun out of pharma giant GSK in 2022, posted pre-tax profits of £1.62bn for 2023, up 0.6%. It now expects revenue to rise 4% - 6% this year.

Revenue grew 4.1% to £11.3bn.

Reporting by Frank Prenesti for Sharecast.com